MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

Inclusion criteria: * Males and Females aged ≥ 18 years (≥ 12 years in PART C) with PVNS or GCTTS with, at least, one measurable site of disease on MRI. * Patients expected to get surgery (PART A of study only). * Vital signs within the ranges: systolic blood pressure 80-150 mmHg , diastolic blood pressure 50-100 mmHg, pulse rate 40-100 bpm, oral body temperature 35.0-37.5°C. * Patients with normal level of serum ionized calcium and phosphate. * Women of child-bearing potential must use highly effective contraception during the study and for 84 days after the study drug infusion. Exclusion criteria: * Patients with major surgery less than 3 months prior to start study drug or who have still side effects of such therapy. * Presence of systemic illness precluding definitive surgery or increasing the risk to patients due to potential immunosuppression. * Use previously of intra-articular treatment within 4 weeks prior dosing. * Patients with dermal change indicative of lymphedema or phlebolymphedema. disease. * Patients with elevated troponin T and/or CK levels (\> 1.5 x ULN for the laboratory) or with history of myositis, rhabdomyolysis or other myopathic disease. * Patients receiving immunosuppressive treatment as well as corticosteroids which cannot be discontinued at least 4 weeks before dosing. * Patients engaged in a resistance exercise training program. * Patients with pacemakers or any metallic objects as exclusion for MRI * Patients with concomitant disease know to g…